Actinium Pharmaceuticals’ Iomab-B improves survival in refractory AML

Actinium Pharmaceuticals announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting in Glasgow. The results showed that an Iomab-B led bone marrow transplant results in higher rates of remissions and durable Complete Remission, which is the primary endpoint of the SIERRA trial, as well as significant improvement in overall survival in TP53 positive patients. The Phase 3 SIERRA trial enrolled 153 patients age 55 and above with active relapsed or refractory acute myeloid leukemia or AML and compared outcomes of patients receiving Iomab-B BMT to those of patients receiving physician’s choice of care in the control arm. In total, 24% of the 153 patients enrolled on SIERRA had a TP53 mutation, which is associated with limited treatment options and poor outcomes.